aspirin + cilostazol

Aspirin + cilostazol is a fixed-dose combination of two antiplatelet agents used primarily for secondary prevention of ischemic stroke, especially in patients with noncardioembolic stroke. Aspirin acts as an irreversible inhibitor of cyclooxygenase-1 (COX-1), thereby inhibiting thromboxane A2 formation and reducing platelet aggregation. Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor that increases intracellular cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation. Clinical trials have shown that dual antiplatelet therapy with aspirin plus cilostazol reduces the risk of recurrent ischemic stroke more effectively than monotherapy, without significantly increasing the risk of severe or life-threatening bleeding. This combination may also slow progression of intracranial artery stenosis compared to aspirin alone[1][2][3][4].

Other names

cilostazol + aspirin